Pharmacokinetics and pharmacodynamics of an orally disintegrating tablet formulation of dexlansoprazole
Open Access
- 29 September 2016
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 9 (6), 759-769
- https://doi.org/10.1177/1756283x16670073
Abstract
Background: : The pharmacokinetics and pharmacodynamics of a novel orally disintegrating tablet (ODT) formulation of delayed-release dexlansoprazole 30 mg was evaluated versus the dexlansoprazole 30 mg capsule in this phase I, open-label, multiple-dose, randomized, two-period crossover study. Methods: : Healthy adults received daily doses of 30 mg dexlansoprazole ODT or 30 mg dexlansoprazole delayed-release capsule for 5 days during two treatment periods, separated by a 7-day washout interval. Blood samples for dexlansoprazole plasma concentrations and intragastric pH measurements were collected through 24 hours postdose on days 1 and 5 of each period. Results: : Bioequivalence between the 30 mg ODT and 30 mg capsule dosage forms was demonstrated by the primary endpoints of dexlansoprazole peak concentration ( Cmax) and systemic exposure (AUC) values contained within the prespecified 90% confidence interval (CI) range of 0.80–1.25. Additional primary endpoints of intragastric mean pH values and percentage of time with pH > 4 over the 24-hour postdose interval were equivalent for dexlansoprazole ODT and dexlansoprazole capsule. Treatment-emergent adverse events were reported in 23% and 28% of participants receiving the ODT and capsule formulations, respectively. Headache was the most common adverse event in both treatment regimens (5.8% with ODT and 6.0% with capsule). Conclusions: : Administration of dexlansoprazole 30 mg ODT or 30 mg capsule provided equivalent plasma exposure when either was administered as a single dose or as once daily doses for 5 days. Pharmacodynamic equivalence between the two formulations was demonstrated by similar intragastric pH parameters on both day 1 and day 5. No effect of day on dexlansoprazole pharmacokinetics was observed. Dexlansoprazole ODT and dexlansoprazole capsule were both well tolerated.Keywords
This publication has 16 references indexed in Scilit:
- Prevalence and risk factors for dysphagia: a USA community studyNeurogastroenterology & Motility, 2014
- Guidelines for the Diagnosis and Management of Gastroesophageal Reflux DiseaseThe American Journal of Gastroenterology, 2013
- Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non‐erosive reflux diseaseAlimentary Pharmacology & Therapeutics, 2009
- Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed‐release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitisAlimentary Pharmacology & Therapeutics, 2009
- Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjectsAlimentary Pharmacology & Therapeutics, 2006
- Pill Swallowing by Adults With DysphagiaJAMA Otolaryngology–Head & Neck Surgery, 2005
- Epidemiology of gastro-oesophageal reflux disease: a systematic reviewGut, 2005
- ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.2001
- Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazoleAlimentary Pharmacology & Therapeutics, 1998
- Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, MinnesotaGastroenterology, 1997